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substantial reductions in doctor demand and substantial soci-
etal cost savings. Since prior research suggests no adverse
impact on adherence to drugs and follow-up of these innova-
tions, serious consideration should be given to policy changes
to adopt substituting for doctor for routine HIV follow-up
care.
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OBJECTIVE: To evaluate all-cause mortality and cost of treat-
ment in patients with refractory invasive aspergillosis (rIA)
treated with either posaconazole or other systemic anti-fungal
(SAF) therapies. METHODS: All-cause mortality and cost of
salvage therapy of posaconazole oral suspension (800 mg/day)
and other SAF treatments were assessed using a multicenter
clinical study in patients with IA refractory to or intolerant of
conventional antifungal therapy. Data from external controls
were collected retrospectively providing a comparative refer-
ence group. All patients had failed to improve or progress with
prior SAF therapies. Prior SAF treatments for the majority of
patients were liposomal amphotericin B, amphotericin B, or
itraconazole. Cases of aspergillosis deemed evaluable by a
blinded data review committee included 107 posaconazole and
86 control subjects (modiﬁed intent-to-treat population). The
populations were comparable regarding pre-speciﬁed demo-
graphic and clinical characteristics. All-cause mortality were
analyzed using the survival technique. Economic evaluations
were conducted using survival data and costs of pharmaco-
therapy one year post therapy (2007 Canadian dollars).
RESULTS: Signiﬁcantly more posaconazole-treated patients
responded to therapy as compared with other SAF therapies.
Patients with rIA treated with posaconazole appeared to confer
a highly signiﬁcant survival beneﬁt over the control cases. The
cumulative rates of survival at 30 days and at the end of
therapy were 74% and 38%, respectively. For controls, those
survival rates were 49% and 22%, respectively. The Kaplan-
Meier survival curves were signiﬁcantly different (P = 0.0003).
In addition, posaconazole appeared to be a cost-saving option
for the treatment of rIA compared with the active comparator
receiving standard SAF treatments ($14,839 vs. $38,158). Sen-
sitivity analyses demonstrated the robustness of the results
over a range of alternative values for costs and outcomes.
CONCLUSION: Treatment with posaconazole compared with
other SAF treatments provided a signiﬁcant survival beneﬁt in
patients with rIA at lower cost of drug therapy.
PIN11
COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES
Flavin JK, Becker RV
Dymaxium Inc,Toronto, ON, Canada
OBJECTIVE: The “AIDS epidemic update” (2007) published
by the United Nations (UN) and World Health Organization
(WHO), reports lower estimates of incidences of persons
infected with HIV globally. This study evaluates the cost
savings of these lower estimates on costs associated with
patients being treated by antiretroviral (ARV) drugs and oppor-
tunistic infection (OI) prophylaxis. METHODS: Estimated dif-
ferences in incidences of persons infected with HIV for the
eight global regions in years 2006 and 2007 were calculated
from UN reports. This difference was then multiplied by the
average percentage of patients on ARV and OI treatment.
Further, to derive the total cost savings associated with the
ARV cohort, the number of patients on ARV medication was
multiplied by a weighted average of ﬁrst and second line ARV
drug costs, lab costs, counseling costs, inpatient costs and out-
patient costs, for each region. Conversely, only counseling and
OI drug costs were included in the total cost of patients receiv-
ing OI prophylaxis treatment, for each region. Costs were
reported in 2006 US dollars. Sensitivity analysis performed on
all key parameters. RESULTS: The reduction of incidences of
persons infected with HIV from 2006 to 2007 resulted in a
total cost savings of $309.5 million, or 42%. Separately, the
patients being treated by ARV drugs attributed a cost savings of
$274.7 million, contrary to patients on OI drugs attributing
$34.8 million to cost savings. The greatest savings were shown
in the Sub-Saharan Africa region ($191.1 million). CONCLU-
SION: Based on the revised estimates, the worldwide savings is
a large percentage of the treatment budget. Notwithstanding
increased incidence rates in subsequent years, these savings
should continue beyond 2007.
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OBJECTIVE: Restricted information exists to guide clinicians in
selecting antibiotics for diabetic foot infections in Colombia.
Because this serious complication causes substantial morbidity,
mortality, and incurs major health care costs, we developed a
decision tree model to determine, from the Ministry of Health’s
perspective, the cost-effectiveness in Colombia of the treatments
recommended by the Infectious Diseases Society of America
guidelines for mild diabetic foot infections. METHODS: A
decision-tree model was developed using TreeAge® Pro-2007
and clinical experts. Success probabilities were derived from
published randomized controlled trials. Drug costs were
obtained from the Farmaprecios Guía de precios sugeridos al
público, promedio del mercado para farmacias independientes.
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D.C. and amputation and hospitalization costs from ISS 2001/
2004 database, with values adjusted to 2007 using the Colom-
bian inﬂation. One-way and two-way sensitivity analyses were
performed to test the robustness of the decision tree model by
varying the clinical success rates and costs of antibiotics. Proba-
bilistic sensitivity analyses were also performed using Monte
Carlo simulations. RESULTS: Clindamycin was cost-effective,
dominating all other choices, and cephalexin had the next best
proﬁle. Expected success rates were 99.4% for clindamycin,
97.8% for cephalexin, 95.4% for amoxicillin-clavulanate,
95.2% for oxacillin and 95.0% for levoﬂoxacin. The expected
cost of clindamycin ($315,200 pesos (USD$157.28)) was lower
than the next best alternative, cephalexin $366,560 pesos
(USD$182.14); a cost difference of $51,360 pesos (USD$24.86)
per patient treated. However, success rates were based on a single
small trial for each drug (n < 30 for each). In sensitivity analyses,
the model/decision was sensitive to changes in efﬁcacy rates and
costs within plausible ranges for clindamycin and cephalexin.
CONCLUSION: Clindamycin was cost-effective in treating mild
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diabetic foot infection but our model had several limitations/
assumptions; consequently, the results should be interpreted
cautiously. More clinical studies to evaluate oral antibiotics effec-
tiveness are needed.
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OBJECTIVE: Posaconazole has been demonstrated to be signiﬁ-
cantly superior to standard azole therapy in preventing invasive
fungal infections (IFIs) (P < 0.001) and in reducing overall mor-
tality (P = 0.048) among patients with prolonged neutropenia. In
this study, cost-effectiveness of posaconazole was evaluated from
the Canadian health care system perspective. METHODS: A
trial-based decision analytical model was developed. Patients
were assumed to receive prophylaxis with posaconazole or stan-
dard azole therapy (ﬂuconazole, 81%; itraconazole, 19%). The
probabilities of experiencing an IFI, IFI-related death, and all-
cause mortality over 100 days post treatment were estimated. To
extrapolate results beyond the trial period, the model was
extended to a lifetime horizon using 1-month Markov cycles in
which mortality rate is speciﬁc to the underlying disease as esti-
mated from Statistics Canada and Surveillance, Epidemiology,
and End Result (SEER) data. Pharmacotherapy and treatment
costs associated with IFIs were estimated using published litera-
ture. The model was used to estimate costs, IFIs avoided, life-
years gained, and the incremental cost-effectiveness ratio (ICER)
of posaconazole versus standard azole therapy (2007 Canadian
dollars). RESULTS: Posaconazole is associated with signiﬁcant
fewer IFIs (0.05 vs. 0.11) (P = 0.003), increased life-years (0.744
vs. 0.728), and (excluding costs of the underlying condition)
slightly lower costs ($7147 vs. $7332) per patient relative to
standard azole therapy over a lifetime horizon. A second-order
probabilistic Monte Carlo sensitivity analysis was conducted to
assess the effects of parameter uncertainty, particularly as they
relate to treatment efﬁcacy and the costs of an IFI. Results indi-
cate that there is a 53% probability that posaconazole is cost
saving versus standard azole therapy and a 70% probability that
the ICER for posaconazole is at or below the $50,000 per life-
year saved threshold. CONCLUSION: In addition to the proven
efﬁcacy, posaconazole appeared to be cost saving relative to
standard azole therapy in the prevention of IFIs among high-risk
neutropenic patients.
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OBJECTIVE: Hepatitis C is a disease affecting approximately
180 million people worldwide (WHO 2006) and is one of the
main causes of chronic hepatic disease. HCV infection
progresses to chronic form in 80% of infected individuals.
Approximately 20% progress to cirrhosis over 20 years and,
consequently, a high risk of developing hepatocellular carci-
noma population. We assessed the incremental cost-effectiveness
ratio (ICER) of peginterferon alfa-2a (40 KD) plus ribavirin
(PEG + RBV) versus interferon alfa-2b plus ribavirin
(IFN + RBV) in the treatment of patients with chronic hepatitis
C under the Brazilian payer perspective. METHODS: A
Markov model was built to estimate the clinical and economic
impact related to the incorporation of peginterferon-alfa-2a (40
KD). Clinical stages were based on liver histology, forms of
cirrhotic decompensation, liver cancer and liver transplantation.
A Delphi panel was performed for evaluating the direct medical
resources related to each clinical stage in chronic hepatitis C, as
well as costs from treatment with peginterferon-alfa-2a (40
KD), interferon alfa-2b and ribavirin. Effectiveness of treatment
with peginterferon-alfa-2a (40 KD) was obtained from a mul-
ticenter, controlled, randomized trial involving 1121 naive
patients with chronic hepatitis C (Fried et al, 2002). The model
comprises a life-time horizon. We have assumed a discount rate
of 3% for both costs and outcomes according to international
recommendations (Gold et al, 1996). A sensitivity analysis was
conducted using second-order Monte Carlo simulation. Tested
parameters were costs per stage, treatment costs, discount rate,
response rate to treatment, inﬂation rate and early patient dis-
tribution. RESULTS: The ICER of PEG + RBV versus no treat-
ment was approximately -R$62,521 per quality-adjusted life
year (QALY) gained. The ICER of PEG + RBV versus
IFN + RBV was approximately -R$20,087 per QALY. CON-
CLUSION: The study suggests peginterferon alfa-2a (40 KD)
and ribavirin to be a dominant therapy for treating hepatitis C
in the private health care system in Brazil.
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OBJECTIVE: Tipranavir plus ritonavir (TPV/r) and an optimized
background (OB) antiretroviral regimen delays virologic failure,
reduces viral load and increases CD4 count compared to patients
treated with comparator protease inhibitors, co-administered
with ritonavir (CPI/r) and OB alone. The objective was to inves-
tigate the long-term cost, outcomes and cost-effectiveness of
TPV/r + OB compared to CPI/r + OB in the Canadian health care
system. METHODS: A Markov model was developed and popu-
lated with information on 48-week viral load and CD4 cell count
response from two randomized controlled trials (RESIST 1 and
RESIST 2) and HAART-era published literature. Resource use
and cost data was obtained from a Canadian study and published
sources. Future costs and outcomes were discounted at 5%. The
analysis calculated costs and outcomes from time of starting
these regimens, until 90% of patients in each strategy had died
(lifetime analysis). Cost-effectiveness was calculated as cost per
life year (LY) gained and cost per quality-adjusted life year
(QALY) gained. RESULTS: Total discounted lifetime costs
for TPV/r + OB was $221,541 compared to $194,466 with
CPI + OB. discounted life expectancy and QALYs were greater
for TPV/r + OB compared to CPI/r + OB by 0.530 yrs and
0.516 QALYs, respectively. Incremental cost-effectiveness of
TPR/r + OB was $51,058 per LY gained and $52,517 per QALY
gained. Sensitivity analysis showed results were robust. CON-
CLUSION: TPV/r + OB provides superior clinical improvement
to a population of highly treated HIV patients with limited
treatment options. TPV/r + OB is predicted to improve life
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